Ru­bius cites some pre­clin­i­cal progress; Xen­cor scores deal with Astel­las; Ei­dos to re­state quar­ter­ly fil­ings

→ Ru­bius Ther­a­peu­tics $RU­BY has post­ed some pos­i­tive — though pre­clin­i­cal — study re­sults on its red blood cell tech, say­ing they were able to track a de­sired im­mune re­sponse us­ing their drugs.The ther­a­pies are de­signed to in­crease the flow of T cells to a tu­mor, mob­bing can­cer cells in the process.

→ Lit­tle Ei­dos $EI­DX, which is go­ing up against the gi­ant Pfiz­er $PFE in de­vel­op­ing a treat­ment de­signed to treat transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM), has run in­to ac­count­ing trou­ble in con­nec­tion with its for­mer au­di­tor PwC. In a fil­ing post­ed on Mon­day, the San Fran­cis­co-based drug de­vel­op­er said af­ter a dis­cus­sion with its new au­di­tor Ernst & Young it will have to re­state fi­nan­cial in­for­ma­tion for the first three quar­ter­ly pe­ri­ods in the year end­ed De­cem­ber 31, 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER